Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyLindsey R. Baden, Hong‐Van Tieu, Daniel J Stieh et al.|The Lancet HIV|2020Cited by 91
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara VectorLindsey R. Baden, Kelly Stanley, Stephen R. Walsh et al.|The Journal of Infectious Diseases|2018Cited by 45
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a StudyDaniel J Stieh, Varun K. Phadke, Dan H. Barouch et al.|The Journal of Infectious Diseases|2022Cited by 36
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Jamie Sanders, Salim Wakabi et al.|npj Vaccines|2024Cited by 19